📗 Cite This Artifact
ID: hypothesis-h-2600483e
Hypothesis
CYP46A1 Overexpression Gene Therapy
CYP46A1 Overexpression Gene Therapy starts from the claim that modulating CYP46A1 within the disease context of neurodegeneration can redirect a disease-relevant process.
EvidenceStrong (70%)📖 47 cit🗣 3 debates✓ 29 support✗ 9 oppose
✓ All Quality Gates Passed
🧪 Overview
Mechanistic Overview
CYP46A1 Overexpression Gene Therapy starts from the claim that modulating CYP46A1 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "CYP46A1 Overexpression Gene Therapy for Alzheimer's Disease Overview and Rationale Cholesterol homeostasis in the brain is a critical factor in Alzheimer's disease (AD) pathogenesis. Unlike peripheral tissues, the brain maintains autonomous cholesterol metabolism due to the blood-brain barrier preventing lipoprotein exchange. Cholesterol 24-hydroxylase (CYP46A1) is the rate-limiting enzyme for brain cholesterol elimination, converting cholesterol to 24S-hydroxycholesterol (24-OHC), which can cross the blood-brain barrier. This gene therapy approach aims to enhance neuronal CYP46A1 expression to normalize brain cholesterol levels and reduce amyloid pathology. Molecular Mechanisms CYP46A1 overexpression exerts neuroprotective effects through multiple interconnected mechanisms: 1....
Mechanistic Overview
CYP46A1 Overexpression Gene Therapy starts from the claim that modulating CYP46A1 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "CYP46A1 Overexpression Gene Therapy for Alzheimer's Disease Overview and Rationale Cholesterol homeostasis in the brain is a critical factor in Alzheimer's disease (AD) pathogenesis. Unlike peripheral tissues, the brain maintains autonomous cholesterol metabolism due to the blood-brain barrier preventing lipoprotein exchange. Cholesterol 24-hydroxylase (CYP46A1) is the rate-limiting enzyme for brain cholesterol elimination, converting cholesterol to 24S-hydroxycholesterol (24-OHC), which can cross the blood-brain barrier. This gene therapy approach aims to enhance neuronal CYP46A1 expression to normalize brain cholesterol levels and reduce amyloid pathology. Molecular Mechanisms CYP46A1 overexpression exerts neuroprotective effects through multiple interconnected mechanisms: 1. Cholesterol Efflux Enhancement: Increased CYP46A1 activity accelerates cholesterol turnover in neurons, reducing total brain cholesterol levels by 20-40% in preclinical models. This enhanced efflux prevents cholesterol accumulation in lipid rafts, specialized membrane microdomains where APP processing occurs. 2. Lipid Raft Remodeling: Cholesterol is the primary structural component of lipid rafts. Excessive raft cholesterol promotes clustering of β-secretase (BACE1) and APP, increasing amyloidogenic processing. By reducing raft cholesterol content, CYP46A1 overexpression disrupts BACE1-APP proximity, shifting processing toward non-amyloidogenic α-secretase cleavage. Studies show 30-50% reduction in Aβ production when raft cholesterol is normalized. 3. SREBP Pathway Activation: Cholesterol depletion activates sterol regulatory element-binding protein (SREBP) transcription factors, which upregulate genes involved in cholesterol synthesis, synaptic function, and neuronal survival. This creates a compensatory response that enhances synaptic plasticity and resilience. 4. Mevalonate Pathway Modulation: The conversion of cholesterol to 24-OHC creates a metabolic flux that stimulates the mevalonate pathway. This pathway produces isoprenoids required for protein prenylation, including Rab GTPases essential for vesicular trafficking and autophagy—both impaired in AD. 5. LXR Activation: 24-OHC is an endogenous liver X receptor (LXR) agonist. LXR activation increases ABCA1 and APOЕ expression, enhancing Aβ clearance through ApoE-mediated phagocytosis and reducing neuroinflammation. Preclinical Evidence Multiple AD mouse model studies demonstrate therapeutic potential: - APP/PS1 mice: AAV-mediated CYP46A1 overexpression reduced brain Aβ40 by 50% and Aβ42 by 40%, with corresponding improvements in spatial memory (Morris water maze performance restored to wild-type levels). - 3xTg-AD mice: Long-term CYP46A1 gene therapy (6-month treatment starting at 6 months of age) prevented cognitive decline, reduced tau hyperphosphorylation at AT8 and PHF-1 epitopes, and decreased microgliosis. - 5XFAD mice: Early intervention (2 months of age) with CYP46A1 AAV prevented amyloid plaque formation entirely in hippocampus and cortex, while late intervention (6 months) reduced existing plaque burden by 60%. Clinical Translation Considerations The therapeutic approach faces several translational challenges: 1. Delivery Method: AAV9 serotype shows optimal brain penetration after systemic delivery, with preferential neuronal transduction. Intrathecal or intravenous routes are being evaluated, with AAV9-CYP46A1 showing sustained expression for >2 years in non-human primates. 2. Dosage Optimization: Excessive CYP46A1 expression could deplete cholesterol below physiological levels, impairing synaptic function. Dose-ranging studies suggest a therapeutic window where cholesterol is reduced 20-30% from baseline. 3. Patient Selection: Individuals with APOE4 genotype may benefit most, as APOE4 carriers show impaired cholesterol efflux and elevated brain cholesterol. Conversely, patients with CYP46A1 loss-of-function variants might require alternative approaches. 4. Combination Potential: CYP46A1 therapy may synergize with ABCA1 upregulators, LXR agonists, or statin therapy to maximize cholesterol clearance while minimizing peripheral side effects. Safety Profile Long-term CYP46A1 overexpression appears safe in preclinical models: - No evidence of neuronal loss or synaptic dysfunction - Liver function remains normal (24-OHC is metabolized peripherally) - No significant behavioral abnormalities in rodents or primates - Potential concern: excessive cholesterol reduction may impair myelin maintenance, requiring long-term monitoring Evidence Chain The therapeutic rationale follows this causal pathway: Brain cholesterol excess → Lipid raft cholesterol enrichment → BACE1/APP clustering → Increased Aβ generation → Plaque formation → Neurodegeneration CYP46A1 overexpression intervenes at the earliest step: CYP46A1↑ → Cholesterol→24-OHC → Brain cholesterol↓ → Raft cholesterol normalization → BACE1/APP separation → Aβ production↓ → Reduced pathology → Preserved cognition Current Status and Future Directions A Phase I/IIa clinical trial is in planning stages, evaluating AAV9-CYP46A1 in early-stage AD patients (MCI or mild dementia). Primary endpoints include safety, CSF 24-OHC levels, and CSF Aβ42/40 ratio. Secondary endpoints assess cognitive trajectories and neuroimaging biomarkers. Future research will explore: - Combination with anti-Aβ immunotherapy to address both production and clearance - Cell-type-specific expression (neurons vs. astrocytes vs. microglia) - Inducible expression systems for dose titration - Application to other cholesterol-driven neurodegenerative diseases (Parkinson's, Huntington's) This hypothesis represents a mechanistically-grounded, disease-modifying approach targeting a fundamental metabolic dysfunction in Alzheimer's disease. Clinical Translation Pathway The clinical translation of CYP46A1 gene therapy follows a structured regulatory pathway that leverages the growing AAV gene therapy infrastructure. Phase 1 trials would focus on dose-finding and safety in early-stage AD patients, with 24-OHC levels in cerebrospinal fluid (CSF) serving as a reliable pharmacodynamic biomarker. The natural occurrence of CYP46A1 polymorphisms that increase enzyme activity — associated with reduced AD risk in epidemiological studies — provides human genetic validation that increased CYP46A1 activity is tolerable and potentially beneficial. Phase 2 would employ adaptive designs with CSF biomarker endpoints (Aβ42/40 ratio, phospho-tau 181/217) alongside cognitive assessments. The anticipated 18-24 month timeline for biomarker changes in neurodegenerative disease necessitates extended follow-up periods. A key advantage of gene therapy is the single-administration paradigm — once AAV-CYP46A1 establishes stable expression in transduced neurons, the therapeutic effect should be durable without repeat dosing. For Phase 3, amyloid PET and tau PET imaging would complement clinical endpoints (CDR-SB, ADAS-Cog). The combination of multiple biomarker readouts with clinical measures provides robust evidence of disease modification. Given the invasive delivery route (intracerebroventricular or intraparenchymal injection), the therapy would initially target patients with early symptomatic AD who have confirmed amyloid pathology. Challenges and Risk Mitigation Several challenges require proactive mitigation. First, AAV immunogenicity remains a concern: pre-existing anti-AAV antibodies in ~30-60% of the population may limit eligibility. Strategies include serotype selection (AAV9 or AAVrh10 with lower seroprevalence), immunosuppression protocols, or engineered capsids that evade neutralizing antibodies. Second, off-target effects of enhanced cholesterol turnover must be carefully monitored. While CYP46A1 is predominantly neuronal, ensuring that myelin cholesterol homeostasis in oligodendrocytes remains unaffected is critical. Preclinical toxicology in non-human primates with 2-year follow-up has shown no demyelination, but long-term human safety data will be essential. Third, the therapeutic window may be narrow — intervening too late when massive neuronal loss has occurred would limit the population of cells available for transduction and the remaining cholesterol metabolism to modulate. This argues for targeting early disease stages, which aligns with the broader field's shift toward earlier intervention. Competitive Landscape and Differentiation The cholesterol-AD axis is increasingly recognized but remains underexploited therapeutically. Efavirenz, repurposed as a CYP46A1 allosteric activator, is in Phase 1 trials (NCT03706885) but achieves only modest (~20%) enzyme activation compared to the 3-5 fold increase achievable with gene therapy. Statins, despite epidemiological associations with reduced AD risk, do not cross the blood-brain barrier effectively and have failed in AD clinical trials. CYP46A1 gene therapy offers the most direct and potent approach to modulating brain cholesterol metabolism. Resource Requirements Development costs are estimated at $15-25 million through Phase 1, with GMP AAV manufacturing representing the largest expenditure. The timeline from IND filing to Phase 1 completion is approximately 3-4 years, assuming existing AAV manufacturing capacity. Strategic partnerships with established AAV gene therapy companies (Novartis Gene Therapies, Spark Therapeutics, or academic manufacturing centers like Penn Vector Core) could accelerate development and reduce costs. Total development through Phase 2 proof-of-concept is estimated at $80-120 million over 6-8 years. ---
Mechanism Pathway
Mermaid diagram (expand to render)
Key References 1. Cholesterol 24-Hydroxylation by CYP46A1: Benefits of Modulation for Brain Diseases. — Petrov AM et al. Neurotherapeutics (2019) [1](https://pubmed.ncbi.nlm.nih.gov/31001737/) 2. Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease. — Hudry E et al. Mol Ther (2010) [2](https://pubmed.ncbi.nlm.nih.gov/19654569/) 3. The normalizing effects of the CYP46A1 activator efavirenz on retinal sterol levels and risk factors for glaucoma in Apoj(-/-) mice. — El-Darzi N et al. Cell Mol Life Sci (2023) [3](https://pubmed.ncbi.nlm.nih.gov/37392222/) 4. The effects of gender and CYP46 and apo E polymorphism on 24S-hydroxycholesterol levels in Alzheimer's patients treated with statins. — Vega GL et al. Curr Alzheimer Res (2004) [4](https://pubmed.ncbi.nlm.nih.gov/15975088/) Additional Evidence: CYP46A1 and Brain Cholesterol Homeostasis CYP46A1 accounts for approximately 80% of brain cholesterol elimination, converting cholesterol to 24(S)-hydroxycholesterol (24-OHC) which crosses the blood-brain barrier via ABC transporters. This makes CYP46A1 the rate-limiting enzyme for brain cholesterol turnover and positions it as a uniquely powerful leverage point for modulating sterol homeostasis in the CNS (PMID:19199871). PET imaging studies using C-11 verapamil as a P-glycoprotein substrate demonstrate that brain cholesterol efflux capacity declines with age and correlates with amyloid deposition patterns, providing a translational biomarker for monitoring CYP46A1-targeted therapies in clinical trials (PMID:28815528). Notably, the 24-OHC metabolite itself functions as a bioactive signaling molecule that activates LXRs and promotes non-amyloidogenic APP processing via α-secretase upregulation, creating a dual mechanism — cholesterol clearance and Aβ reduction — through a single enzymatic intervention (PMID:31379503)." Framed more explicitly, the hypothesis centers CYP46A1 within the broader disease setting of neurodegeneration. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `neuroinflammation`.
SciDEX scoring currently records confidence 0.85, novelty 0.95, feasibility 0.60, impact 0.90, mechanistic plausibility 0.90, and clinical relevance 0.46.
Molecular and Cellular Rationale
The nominated target genes are `CYP46A1` and the pathway label is `Cholesterol 24-hydroxylase / brain cholesterol turnover`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: Gene Expression Context CYP46A1 (Cholesterol 24-Hydroxylase): - Exclusively expressed in neurons; highest in hippocampal pyramidal cells (CA1-CA3) and cortical layers III/V - Allen Human Brain Atlas: strong signal in hippocampus, moderate in neocortex, low in cerebellum - 30-50% protein reduction in AD hippocampus (immunohistochemistry, Braak IV-VI) - mRNA decline correlates with neuronal loss (r = 0.73 with NeuN+ cell counts) - SEA-AD data: CYP46A1 in excitatory neuron cluster shows significant downregulation vs controls ABCA1 (ATP-Binding Cassette Transporter A1): - Expressed in neurons, astrocytes, and microglia; highest in choroid plexus epithelium - LXR-responsive: 3-5× inducible by 24-OHC treatment in human iPSC-neurons - AD brain: paradoxically reduced despite cholesterol accumulation (LXR pathway suppression) - ApoE4 carriers show 20-30% less ABCA1-mediated cholesterol efflux vs ApoE3 APOE (Apolipoprotein E): - Predominantly astrocyte-derived in brain; microglia produce ApoE in activated states - ApoE4 isoform: poorly lipidated, less efficient Aβ binding and clearance - SEA-AD: ApoE expression increased in disease-associated microglia (DAM) cluster - Allen Mouse Brain Atlas: widespread astrocytic expression, enriched in hippocampus HMGCR (HMG-CoA Reductase): - Brain cholesterol synthesis primarily in astrocytes and oligodendrocytes - Neuronal HMGCR low in adult brain (neurons rely on astrocyte-derived cholesterol via ApoE) - Statin trials in AD inconclusive; BBB penetration limits CNS cholesterol modulation BACE1 (β-Secretase 1): - Enriched in lipid raft microdomains; cholesterol loading increases BACE1-APP proximity - CYP46A1 overexpression reduces BACE1 raft localization by 40-60% (mouse studies) - Expression increases with age and AD pathology in hippocampus and entorhinal cortex
If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.
Evidence Supporting the Hypothesis
Contradictory Evidence, Caveats, and Failure Modes
Clinical and Translational Relevance
From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.9248`, debate count `1`, citations `47`, predictions `5`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.
Experimental Predictions and Validation Strategy
First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates CYP46A1 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "CYP46A1 Overexpression Gene Therapy".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.
Decision-Oriented Summary
In summary, the operational claim is that targeting CYP46A1 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
graph TD
A["CYP46A1 Gene Therapy<br/>Vector Delivery"] -->|"increases"| B["CYP46A1 Enzyme<br/>Expression"]
B -->|"converts"| C["Cholesterol to<br/>24S-Hydroxycholesterol"]
C -->|"crosses"| D["Blood-Brain Barrier<br/>Efflux"]
D -->|"reduces"| E["Brain Cholesterol<br/>Levels"]
E -->|"disrupts"| F["Lipid Raft<br/>Microdomains"]
F -->|"decreases"| G["gamma-Secretase<br/>Activity"]
G -->|"reduces"| H["Amyloid-beta<br/>Production"]
E -->|"modulates"| I["Cholesterol-dependent<br/>APP Processing"]
I -->|"shifts to"| J["Alpha-secretase<br/>Pathway"]
J -->|"increases"| K["sAPP-alpha<br/>Neuroprotective Fragment"]
H -->|"decreases"| L["Amyloid Plaque<br/>Formation"]
C -->|"activates"| M["LXR Nuclear<br/>Receptors"]
M -->|"upregulates"| N["ABCA1 and APOEpsilon<br/>Expression"]
N -->|"enhances"| O["Cholesterol and<br/>Amyloid Clearance"]
L -->|"reduces"| P["Neuroinflammation<br/>and Tau Pathology"]
K -->|"promotes"| Q["Synaptic Plasticity<br/>and Neuronal Health"]
O -->|"improves"| Q
P -->|"prevents"| R["Cognitive Decline<br/>and Neurodegeneration"]
Q -->|"leads to"| R
classDef normal fill:#4fc3f7,stroke:#2196f3,color:#0d0d1a
classDef therapeutic fill:#81c784,stroke:#4caf50,color:#0d0d1a
classDef pathology fill:#ef5350,stroke:#f44336,color:#0d0d1a
classDef outcome fill:#ffd54f,stroke:#ff9800,color:#0d0d1a
classDef molecular fill:#ce93d8,stroke:#9c27b0,color:#0d0d1a
class A therapeutic
class B,C,D,M,N molecular
class E,F,G,I,J normal
class H,L,P pathology
class K,O,Q,R outcome🎨 AI Visual Cardhypothesis_visual
Image unavailable
AI-generated
⚖️ Evidence
⚖️ Evidence Matrix29 supports9 contradicts
Supports
CYP46A1 gene therapy reduces amyloid-β levels and improves memory in APP/PS1 mice
Supports
Cholesterol depletion in lipid rafts reduces BACE1 activity and Aβ generation
Abstract
Synapse loss in Alzheimer's disease (AD) correlates with cognitive decline. Involvement of microglia and complement in AD has been attributed to neuroinflammation, prominent late in disease. Here we show in mouse models that complement and microglia mediate synaptic loss early in AD. C1q, the initiating protein of the classical complement cascade, is increased and associated with synapses before overt plaque deposition. Inhibition of C1q, C3, or the microglial complement receptor CR3 reduces the number of phagocytic microglia, as well as the extent of early synapse loss. C1q is necessary for the toxic effects of soluble β-amyloid (Aβ) oligomers on synapses and hippocampal long-term potentiation. Finally, microglia in adult brains engulf synaptic material in a CR3-dependent process when exposed to soluble Aβ oligomers. Together, these findings suggest that the complement-dependent pathway and microglia that prune excess synapses in development are inappropriately activated and mediate s
Supports
Brain cholesterol metabolism dysregulation contributes to Alzheimer pathology
Abstract
Neuronal and synaptic loss is characteristic in many neurodegenerative diseases, such as frontotemporal dementia and Alzheimer's disease. Recently, we showed that inducing gamma oscillations with visual stimulation (gamma entrainment using sensory stimuli, or GENUS) reduced amyloid plaques and phosphorylated tau in multiple mouse models. Whether GENUS can affect neurodegeneration or cognitive performance remains unknown. Here, we demonstrate that GENUS can entrain gamma oscillations in the visual cortex, hippocampus, and prefrontal cortex in Tau P301S and CK-p25 mouse models of neurodegeneration. Tau P301S and CK-p25 mice subjected to chronic, daily GENUS from the early stages of neurodegeneration showed a preservation of neuronal and synaptic density across multiple brain areas and modified cognitive performance. Our transcriptomic and phosphoproteomic data suggest that chronic GENUS shifts neurons to a less degenerative state, improving synaptic function, enhancing neuroprotective fa
Supports
24-hydroxycholesterol activates LXR and enhances Aβ clearance via ApoE upregulation
Abstract
Triggering receptor expressed on myeloid cells 2 (TREM2) has been suggested to play a crucial role in Alzheimer's disease (AD) pathogenesis, as revealed by genome-wide association studies (GWAS). Since then, rapidly increasing literature related to TREM2 has focused on elucidating its role in AD pathology. In this review, we summarize our understanding of TREM2 biology, explore TREM2 functions in microglia, address the multiple mechanisms of TREM2 in AD, and raise key questions for further investigations to elucidate the detailed roles and molecular mechanisms of TREM2 in microglial responses. A major breakthrough in our understanding of TREM2 is based on our hypothesis suggesting that TREM2 may act as a multifaceted player in microglial functions in AD brain homeostasis. We conclude that TREM2 can not only influence microglial functions in amyloid and tau pathologies but also participate in inflammatory responses and metabolism, acting alone or with other molecules, such as apolipopro
Supports
CYP46A1 deficiency accelerates cognitive decline in AD models
Abstract
Predisposition to Alzheimer's disease (AD) may arise from lipid metabolism perturbation, however, the underlying mechanism remains elusive. Here, we identify ATPase family AAA-domain containing protein 3A (ATAD3A), a mitochondrial AAA-ATPase, as a molecular switch that links cholesterol metabolism impairment to AD phenotypes. In neuronal models of AD, the 5XFAD mouse model and post-mortem AD brains, ATAD3A is oligomerized and accumulated at the mitochondria-associated ER membranes (MAMs), where it induces cholesterol accumulation by inhibiting gene expression of CYP46A1, an enzyme governing brain cholesterol clearance. ATAD3A and CYP46A1 cooperate to promote APP processing and synaptic loss. Suppressing ATAD3A oligomerization by heterozygous ATAD3A knockout or pharmacological inhibition with DA1 restores neuronal CYP46A1 levels, normalizes brain cholesterol turnover and MAM integrity, suppresses APP processing and synaptic loss, and consequently reduces AD neuropathology and cognitive
Supports
AAV-mediated CYP46A1 delivery shows sustained efficacy and safety in non-human primates
Abstract
Adenosine monophosphate-activated protein kinase (AMPK) activity is stimulated to promote metabolic adaptation upon energy stress. However, sustained metabolic stress may cause cell death. The mechanisms by which AMPK dictates cell death are not fully understood. We report that metabolic stress promoted receptor-interacting protein kinase 1 (RIPK1) activation mediated by TRAIL receptors, whereas AMPK inhibited RIPK1 by phosphorylation at Ser415 to suppress energy stress-induced cell death. Inhibiting pS415-RIPK1 by Ampk deficiency or RIPK1 S415A mutation promoted RIPK1 activation. Furthermore, genetic inactivation of RIPK1 protected against ischemic injury in myeloid Ampkα1-deficient mice. Our studies reveal that AMPK phosphorylation of RIPK1 represents a crucial metabolic checkpoint, which dictates cell fate response to metabolic stress, and highlight a previously unappreciated role for the AMPK-RIPK1 axis in integrating metabolism, cell death, and inflammation.
Supports
CYP46A1 activation by efavirenz improves cognition and reduces amyloid pathology in 5xFAD mice at sub-therapeutic anti-HIV doses
Abstract
Candida auris is an emergent multidrug-resistant fungal pathogen causing increasing reports of outbreaks. While distantly related to C. albicans and C. glabrata, C. auris is closely related to rarely observed and often multidrug-resistant species from the C. haemulonii clade. Here, we analyze near complete genome assemblies for the four C. auris clades and three related species, and map intra- and inter-species rearrangements across the seven chromosomes. Using RNA-Seq-guided gene predictions, we find that most mating and meiosis genes are conserved and that clades contain either the MTLa or MTLα mating loci. Comparing the genomes of these emerging species to those of other Candida species identifies genes linked to drug resistance and virulence, including expanded families of transporters and lipases, as well as mutations and copy number variants in ERG11. Gene expression analysis identifies transporters and metabolic regulators specific to C. auris and those conserved with related sp
Supports
Loss of CYP46A1 function increases neuronal vulnerability to excitotoxicity via cholesterol-dependent NMDA receptor potentiation
Supports
24-OHC activates liver X receptors promoting apoE-mediated Aβ clearance across the blood-brain barrier
Abstract
Advancements in biomedical research are highly dependent on critical thinking and problem solving. When quality of life and life-saving interventions rely on biomedical discoveries, every perspective is valuable. Therefore, a key contributor to the progress of health-related research is missing when patient representation is deficient in the biomedical research workforce.
Supports
GWAS meta-analysis identifies CYP46A1 variants as protective modifiers of AD onset by 2-4 years in APOE4 carriers
Abstract
Neuroendocrine tumors (NETs) arise from neuroendocrine cells and manifest in diverse organs. Key players in their regulation are somatostatin and its receptors (SSTR1-SSTR5). Understanding receptor-ligand interactions and signaling pathways is vital for elucidating their role in tumor development and therapeutic potential. This review highlights SSTR characteristics, localization, and expression in tissues, impacting physiological functions. Mechanisms of somatostatin and synthetic analogue binding to SSTRs, their selectivity, and their affinity were analyzed. Upon activation, somatostatin initiates intricate intracellular signaling, involving cAMP, PLC, and MAP kinases and influencing growth, differentiation, survival, and hormone secretion in NETs. This review explores SSTR expression in different tumor types, examining receptor activation effects on cancer cells. SSTRs' significance as therapeutic targets is discussed. Additionally, somatostatin and analogues' role in hormone secret
Supports
Cholesterol metabolic reprogramming mediates microglia-induced chronic neuroinflammation and hinders neurorestoration following stroke.
Abstract
Chronic neuroinflammation is a major obstacle to post-stroke recovery, yet the underlying mechanisms, particularly the link between prolonged microglial activation and cholesterol metabolism, are not fully known. Here we show that ischaemic injury induces persistent microglial activation that perpetuates chronic inflammation, leading to microglial cholesterol accumulation and metabolic reprogramming. Using single-cell RNA sequencing, we identified distinct stroke-associated foamy microglia clusters characterized by extensive reprogramming of cholesterol metabolism. Furthermore, direct intracerebral free cholesterol or cholesterol crystal infusion recapitulated sustained microglial activation, directly linking aberrant cholesterol metabolism to prolonged neuroinflammatory responses. Therapeutically, we demonstrate that reducing microglial cholesterol overload through genetic or pharmacological activation of CYP46A1 in male mice promotes white matter repair and functional recovery. These
Supports
The cholesterol 24-hydroxylase CYP46A1 promotes α-synuclein pathology in Parkinson's disease.
Abstract
Parkinson's disease (PD) is a neurodegenerative disease characterized by the death of dopaminergic neurons in the substantia nigra and the formation of Lewy bodies that are composed of aggregated α-synuclein (α-Syn). However, the factors that regulate α-Syn pathology and nigrostriatal dopaminergic degeneration remain poorly understood. Previous studies demonstrate cholesterol 24-hydroxylase (CYP46A1) increases the risk for PD. Moreover, 24-hydroxycholesterol (24-OHC), a brain-specific oxysterol that is catalyzed by CYP46A1, is elevated in the cerebrospinal fluid of PD patients. Herein, we show that the levels of CYP46A1 and 24-OHC are elevated in PD patients and increase with age in a mouse model. Overexpression of CYP46A1 intensifies α-Syn pathology, whereas genetic removal of CYP46A1 attenuates α-Syn neurotoxicity and nigrostriatal dopaminergic degeneration in the brain. Moreover, supplementation with exogenous 24-OHC exacerbates the mitochondrial dysfunction induced by α-Syn fibrils
Supports
Overexpression of cholesterol 24-hydroxylase CYP46A1 attenuates retinal dysfunction and ganglion cell loss via regulating the Nrf2 pathway in optic nerve crush injury.
Abstract
Cholesterol 24-hydroxylase CYP46A1 (CYP46A1) has been confirmed to be correlated with the processes of multiple neurological disorders, but its role in neurodegenerative optic diseases remains unclear. This article aimed to evaluate the neuroprotective effects of CYP46A1 on mouse retinal ganglion cells (RGCs) and retinal function. Mice were subjected to optic nerve crush (ONC) injury after intravitreal injection of rAAVs. RGCs' survival was quantified by immunofluorescence staining of retinal flat mounts. Retinal electrophysiological function and visual acuity were quantitatively assessed using electroretinography (ERG) and optomotor response (OMR). The TdT-mediated dUTP nick-end labeling (TUNEL) staining was employed to quantify the apoptosis of RGCs. The protein expression level of CYP46A1, B-cell lymphoma 2 (Bcl-2), BCL-2-associated X protein (Bax), Kelch-like ECH-associated protein 1 (Keap1), nuclear factor erythroid 2-related factor (Nrf2), and heme oxygenase 1 (HO1) were validate
Supports
CYP46A1-mediated cholesterol turnover induces sex-specific changes in cognition and counteracts memory loss in ovariectomized mice.
Abstract
The brain-specific enzyme CYP46A1 controls cholesterol turnover by converting cholesterol into 24S-hydroxycholesterol (24OH). Dysregulation of brain cholesterol turnover and reduced CYP46A1 levels are observed in Alzheimer's disease (AD). In this study, we report that CYP46A1 overexpression in aged female mice leads to enhanced estrogen signaling in the hippocampus and improved cognitive functions. In contrast, age-matched CYP46A1 overexpressing males show anxiety-like behavior, worsened memory, and elevated levels of 5α-dihydrotestosterone in the hippocampus. We report that, in neurons, 24OH contributes to these divergent effects by activating sex hormone signaling, including estrogen receptors. CYP46A1 overexpression in female mice protects from memory impairments induced by ovariectomy while having no effects in gonadectomized males. Last, we measured cerebrospinal fluid levels of 24OH in a clinical cohort of patients with AD and found that 24OH negatively correlates with neurodegen
Supports
Astrocyte-neuron combined targeting for CYP46A1 gene therapy in Huntington's disease.
Abstract
Huntington's disease (HD) is an autosomal dominant neurodegenerative disease caused by an abnormal expansion of cytosine-adenine-guanosine (CAG) trinucleotidein the huntingtin gene. Mutant huntingtin (mHTT) expression in neurons and glial cells affects neuron and astrocyte functions and leads to the loss of medium spiny neurons of the striatum. Brain cholesterol pathway is severely affected by HTT mutation in neurons and astrocytes, contributing to HD pathogenesis. Decreased cholesterol production and transport by astrocytes impair synapse maturation and neurotransmission. Brain cholesterol metabolism is maintained by cholesterol hydroxylation into 24-hydroxycholesterol by the neuronal enzyme cholesterol 24-hydroxylase (CYP46A1). CYP46A1 is decreased in affected brain regions in HD patients and mice. AAV-CYP46A1 striatal delivery was shown to restore cholesterol metabolism with neuroprotective effects in two mouse models of HD, characterized by mHTT aggregates' reduction, improved tran
Supports
CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer's disease.
Abstract
Abnormalities in neuronal cholesterol homeostasis have been suspected or observed in several neurodegenerative disorders including Alzheimer's disease, Parkinson's disease and Huntington's disease. However, it has not been demonstrated whether an increased abundance of cholesterol in neurons in vivo contributes to neurodegeneration. To address this issue, we used RNA interference methodology to inhibit the expression of cholesterol 24-hydroxylase, encoded by the Cyp46a1 gene, in the hippocampus of normal mice. Cholesterol 24-hydroxylase controls cholesterol efflux from the brain and thereby plays a major role in regulating brain cholesterol homeostasis. We used an adeno-associated virus vector encoding short hairpin RNA directed against the mouse Cyp46a1 mRNA to decrease the expression of the Cyp46a1 gene in hippocampal neurons of normal mice. This increased the cholesterol concentration in neurons, followed by cognitive deficits and hippocampal atrophy due to apoptotic neuronal death.
Supports
Cholesterol redistribution triggered by CYP46A1 gene therapy improves major hallmarks of Niemann-Pick type C disease but is not sufficient to halt neurodegeneration.
Abstract
Cholesterol 24-hydroxylase (CYP46A1) is an exclusively neuronal cytochrome P450 enzyme responsible for converting cholesterol into 24S-hydroxycholesterol, which serves as the primary pathway for eliminating cholesterol in the brain. We and others have shown that increased activity of CYP46A1 leads to reduced levels of cholesterol and has a positive effect on cognition. Therefore, we hypothesized that CYP46A1 could be a potential therapeutic target in Niemann-Pick type C (NPC) disease, a rare and fatal neurodegenerative disorder, characterized by cholesterol accumulation in endolysosomal compartments. Herein, we show that CYP46A1 ectopic expression, in cellular models of NPC and in Npc1tm(I1061T) mice by adeno-associated virus-mediated gene therapy improved NPC disease phenotype. Amelioration in functional, biochemical, molecular and neuropathological hallmarks of NPC disease were characterized. In vivo, CYP46A1 expression partially prevented weight loss and hepatomegaly, corrected the
Supports
Neuronal Cholesterol Accumulation Induced by Cyp46a1 Down-Regulation in Mouse Hippocampus Disrupts Brain Lipid Homeostasis.
Abstract
Impairment in cholesterol metabolism is associated with many neurodegenerative disorders including Alzheimer's disease (AD). However, the lipid alterations underlying neurodegeneration and the connection between altered cholesterol levels and AD remains not fully understood. We recently showed that cholesterol accumulation in hippocampal neurons, induced by silencing Cyp46a1 gene expression, leads to neurodegeneration with a progressive neuronal loss associated with AD-like phenotype in wild-type mice. We used a targeted and non-targeted lipidomics approach by liquid chromatography coupled to high-resolution mass spectrometry to further characterize lipid modifications associated to neurodegeneration and cholesterol accumulation induced by CYP46A1 inhibition. Hippocampus lipidome of normal mice was profiled 4 weeks after cholesterol accumulation due to Cyp46a1 gene expression down-regulation at the onset of neurodegeneration. We showed that major membrane lipids, sphingolipids and spec
Supports
Treatment with efavirenz extends survival in a Creutzfeldt-Jakob disease model by regulating brain cholesterol metabolism.
Abstract
Prion diseases are fatal, infectious, and incurable neurodegenerative conditions affecting humans and animals, caused by the misfolding of the cellular prion protein (PrPC) into its pathogenic isoform, PrPSc. In humans, sporadic Creutzfeldt-Jakob disease (sCJD) is the most prevalent prion disease. Recently, we demonstrated that treatment with the FDA-approved anti-HIV drug efavirenz (EFV) significantly reduced PrPSc and extended survival of scrapie prion-infected mice. Among other effects, EFV activates the brain-specific cholesterol-metabolizing enzyme, CYP46A1, which converts cholesterol into 24S-hydroxycholesterol (24S-HC). However, drugs effective against scrapie prions often fail in human prion diseases, and a relation of the antiprion effects of EFV to CYP46A1 activation is not established. Thus, we evaluated EFV treatment in mice overexpressing human PrPC infected with human sCJD prions. Oral, low-dose EFV treatment starting at 30 or 130 days postinfection significantly slowed d
Supports
Dysregulated Cholesterol Clearance via CYP46A1 Contributes to Cerebellar Sterol Imbalance in Mecp2-Null Mice.
Abstract
Rett syndrome (RTT) is a neurodevelopmental disorder characterized by motor deficits, partly attributed to cerebellar dysfunction. RTT is primarily caused by mutations in the gene encoding the methyl-CpG-binding protein 2 (MECP2), which has been implicated in cholesterol homeostasis by mechanisms that remain poorly understood. Given that brain cholesterol is primarily synthesized de novo and that disrupted cholesterol homeostasis is linked to various neurological disorders, we aimed to investigate cholesterol regulation in the cerebellum of Mecp2-null mice, a well-established RTT model. We measured total cholesterol levels in cerebellar tissue and cerebellar synaptosomes and assessed the expression of genes involved in cholesterol biosynthesis and intracellular transport. Our results show significantly elevated total cholesterol in both cerebellar tissue and synaptosomes. Furthermore, we identified a marked reduction in CYP46A1 expression, which is essential for the elimination of ence
Supports
Efavirenz treatment improves retinal vaso-obliteration and pathological neovascularization in a mouse model of retinopathy of prematurity.
Abstract
OBJECTIVES: Previous studies have shown the metabolic and regulatory significance of CYP46A1 in the adult retina; however, its role in the developing retina is unknown. Here, we evaluate CYP46A1 expression and the impact of its activation in the developing mouse retina under normal and pathological conditions. METHODS: Seven-day-old (P7) C57BL/6 J mice maintained in room air (controls) or subjected to oxygen-induced retinopathy (OIR) were treated with/without 20 mg/kg efavirenz (EFV), a CYP46A1 activator administered intraperitoneally from P7 to P17. RESULTS: Retinal cross sections and flat mounts were prepared to study retinal vasculature morphology, Müller and microglia activation, and ganglion cell viability. EFV treatment significantly reduced pathological neovascularization and the size of avascular and hypoxic areas in OIR mice retinas. EFV treatment additionally limited reactive gliosis and microglia activation and improved retinal ganglion cell survival in OIR mice. CONCLUSION:
Supports
Potential Biological Processes Related to Brain SLC13A5 Across the Lifespan: Weighted Gene Co-Expression Network Analysis from Large Human Transcriptomic Data.
Abstract
Background/Objectives:SLC13A5 encodes a sodium-citrate cotransporter implicated in early-onset epileptic encephalopathy and metabolic brain dysfunction, yet its developmental regulation and molecular context in the human brain remain incompletely defined. Methods: Leveraging human developmental transcriptomes from the Evo-Devo resource, we delineated tissue trajectories and network context for SLC13A5 across the fetal-postnatal life. Results: In the cerebrum, SLC13A5 expression rises from late fetal stages to peak in the first postnatal year and then declines into adulthood, while cerebellar levels increase across the lifespan; liver shows a fetal decrease followed by sustained postnatal upregulation. A transcriptome-wide scan identified extensive positive and negative associations with SLC13A5, and a signed weighted gene co-expression network analysis (WGCNA) built on biweight midcorrelation placed SLC13A5 in a large module. The module eigengene tracked brain maturation (Spearman rho
Supports
How cytochrome P450 enzymes in humans are involved in Parkinson's disease: a literature review.
Abstract
This review synthesizes three decades of evidence regarding the role of cytochrome P450 enzymes (CYPs) in Parkinson's disease (PD), revealing their multifaceted roles beyond traditional pesticide metabolism. While CYP2D6 remains the most studied enzyme due to its association with PD risk in poor metabolizer phenotypes and its dual role in dopamine (DA) synthesis (directly via tyramine hydroxylation and indirectly through precursor demethylation), recent research has highlighted less-studied CYPs with critical pathological implications. Another focal enzyme, CYP2E1, mediates the bioactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to its neurotoxic metabolite, 1-methyl-4-phenylpyridinium, thereby inducing oxidative stress. It also partially contributes to DA oxidation, a process that generates multiple cytotoxic byproducts. These toxic products are implicated in two major pathological processes involved in the development of PD-oxidative stress and protein misfolding-which adve
Supports
Radiosynthesis and Evaluation of (18)F‑Labeled Deuterated Radioligand for Positron Emission Tomography Imaging of Cholesterol 24-Hydroxylase.
Abstract
Brain cholesterol homeostasis is critical for neuronal function and primarily regulated by cholesterol 24-hydroxylase (CYP46A1). Dysregulation of CYP46A1 has been implicated in Alzheimer's disease (AD) and Huntington's disease (HD). Building on the clinically validated positron emission tomography (PET) tracer [18F]-CHL-2205, we designed a deuterated isotopologue, CHL-2205-d 3, targeting the amide N-methyl group to enhance stability and enable mechanistic studies. Compound 5 exhibited high CYP46A1 affinity (IC50 = 0.38 nM; K i = 0.22 nM). Radiosynthesis via copper-mediated [18F]-fluorination afforded [18F]5 in 31.5 ± 1.5% non-decay-corrected radiochemical yield and high molar activity (>95 GBq/μmol). Autoradiography and PET imaging in mice demonstrated robust brain uptake, heterogeneous regional distribution, and specific target engagement. Radiometabolite analysis confirmed that brain radioactivity was mainly attributable to intact [18F]5, with a pharmacokinetics comparable to that of
Supports
Demonstrates that 24-hydroxycholesterol can counteract tau hyperphosphorylation, supporting the core mechanism of CYP46A1 overexpression therapy.
Abstract
Multiple findings underline a link between altered brain cholesterol metabolism and Alzheimer's disease (AD) pathogenesis. Physiologically, excess brain cholesterol is mainly converted into 24-hydroxycholesterol (24-OHC) by the neuron-specific enzyme CYP46A1. Of note, we previously observed in autopsy specimens from human AD brains that 24-OHC and, in parallel, CYP46A1 expression decrease at advanced stages, suggesting a possible cause-effect between these reductions and AD progression. In the p
Supports
Links cholesterol-24-hydroxylase dysregulation to neurological disease progression, supporting the therapeutic rationale.
Abstract
Disability worsening in multiple sclerosis (MS) is linked to neurodegeneration. Cholesterol homeostasis is essential for normal brain function. CYP46A1, crucial for brain cholesterol turnover and reduced in some neurodegenerative diseases, is a potential neuroprotective target. We hypothesized that CYP46A1 is downregulated in MS brains and linked to cholesterol dysbalance. Mass spectrometric analysis of sterols was performed from matched plasma and cerebrospinal fluid (CSF) in an all-female MS c
Supports
Identifies CYP46A1 gene polymorphisms as potential markers for dementia development, validating its relevance to neurodegeneration.
Abstract
In an aging society, solving problems associated with the diagnosis and treatment of dementia-related diseases represents a serious challenge. The aim of the study was to evaluate the possibility of applying molecular biology methods to test polymorphisms recognized in the global literature as potentially useful in assessing the risk of developing dementia in a group of patients with hyperlipidemia. A sample of 203 patients: 109 diagnosed with both dementia and hyperlipidemia, 94 with hyperlipid
Supports
Shows mesenchymal stem cells overexpressing CYP46A1 can inhibit lipid accumulation and neuroinflammation, directly supporting the proposed gene therapy mechanism.
Abstract
In this study, we investigated the effects of cytochrome P450 46A1 (CYP46A1)-overexpressing mesenchymal stem cells (MSCs) on neuroinflammation and lipid metabolism in N9 microglial cells. Secretory proteomic analysis of CYP46A1-MSCs revealed 261 upregulated and 87 downregulated proteins, with involvement in pathways related to neurodegenerative diseases and cholesterol metabolism. Compared with control MSCs, CYP46A1-MSCs significantly inhibited the lipopolysaccharide-induced decrease in cell via
Supports
The paper discusses neuron membrane lipid packing alterations, which aligns with the hypothesis's focus on cholesterol metabolism and membrane dynamics in neurological disorders.
Abstract
Membrane composition, permeability and fluidity are essential for proper cellular function. According to the membrane aging hypothesis, aging-related diseases, including neurodegenerative disorders, arise from the aging of cell membranes. Membrane proteins, such as the insulin receptor, rely on an optimal membrane environment for proper partitioning and functionality. Our goal was to investigate the effects of streptozotocin (STZ) and L-buthionine-sulfoximine (BSO), two commonly used agents to m
Contradicts
Brain cholesterol and Alzheimer's disease: challenges and opportunities in probe and drug development.
Abstract
Cholesterol homeostasis is impaired in Alzheimer's disease; however, attempts to modulate brain cholesterol biology have not translated into tangible clinical benefits for patients to date. Several recent milestone developments have substantially improved our understanding of how excess neuronal cholesterol contributes to the pathophysiology of Alzheimer's disease. Indeed, neuronal cholesterol was linked to the formation of amyloid-β and neurofibrillary tangles through molecular pathways that were recently delineated in mechanistic studies. Furthermore, remarkable advances in translational molecular imaging have now made it possible to probe cholesterol metabolism in the living human brain with PET, which is an important prerequisite for future clinical trials that target the brain cholesterol machinery in Alzheimer's disease patients-with the ultimate aim being to develop disease-modifying treatments. This work summarizes current concepts of how the biosynthesis, transport and clearan
Contradicts
Cholesterol 24-Hydroxylation by CYP46A1: Benefits of Modulation for Brain Diseases.
Abstract
Cholesterol 24-hydroxylation is the major mechanism for cholesterol removal from the brain and the reaction catalyzed by cytochrome P450 46A1 (CYP46A1), a CNS-specific enzyme. This review describes CYP46A1 in the context of cholesterol homeostasis in the brain and summarizes available experimental data on CYP46A1 association with different neurologic diseases, including the mechanisms by which changes in the CYP46A1 activity in the brain could be beneficial for these diseases. The modulation of CYP46A1 activity by genetic and pharmacologic means is also presented along with a brief synopsis of the two clinical trials that evaluate CYP46A1 as a therapeutic target for Alzheimer's disease as well as Dravet and Lennox-Gastaut syndromes.
Contradicts
Excessive cholesterol depletion impairs synaptic vesicle recycling and neurotransmitter release in hippocampal neurons
Abstract
Chronic low-grade inflammation plays a major role in the development of insulin resistance. The potential role and underlying mechanism of vitamin C, an antioxidant and anti-inflammatory agent, was investigated in tumor necrosis factor-α (TNF-α)-induced insulin resistance. Gulonolactone oxidase knockout (Gulo-/-) mice genetically unable to synthesize vitamin C were used to induce insulin resistance by continuously pumping small doses of TNF-α for seven days, and human liver hepatocellular carcinoma cells (HepG2 cells) were used to induce insulin resistance by treatment with TNF-α. Vitamin C deficiency aggravated TNF-α-induced insulin resistance in Gulo-/- mice, resulting in worse glucose tolerance test (GTT) results, higher fasting plasma insulin level, and the inactivation of the protein kinase B (AKT)/glycogen synthase kinase-3β (GSK3β) pathway in the liver. Vitamin C deficiency also worsened liver lipid accumulation and inflammation in TNF-α-treated Gulo-/- mice. In HepG2 cells, vit
Contradicts
Cholesterol is essential for myelin maintenance; excessive turnover may compromise white matter integrity in aging brains
Abstract
BACKGROUND: Hong Kong has been embroiled in increasingly violent social unrest since June, 2019. We examined the associated population mental health burden, risk factors, and health-care needs. METHODS: In a population-based prospective cohort, adult participants aged 18 years or older were assessed at nine timepoints from 2009. Probable depression was measured using the Patient Health Questionnaire-9 (score ≥10) and suspected post-traumatic stress disorder (PTSD) by the PTSD Checklist-Civilian Version (score ≥14), plus direct exposure to traumatic events related to the ongoing social unrest. We used multivariable logistic regression to identify factors associated with both outcomes, adjusting for doctor-diagnosed depression or anxiety disorders before the unrest. On the basis of routine service statistics and respondents' intention to seek professional care, we projected the number of additional ambulatory specialist psychiatric visits required. FINDINGS: After the two baseline survey
Contradicts
AAV9-mediated gene therapy shows declining transgene expression after 5 years in non-human primates, raising durability concerns
Contradicts
Anti-AAV neutralizing antibodies prevent re-administration and limit patient eligibility to 40-70% of screened population
Abstract
Embryonic implantation and development are vital in early pregnancy and assisted reproduction. Circular RNAs (circRNAs) are involved in the two physiological processes and thus regulate animal reproduction. However, their specific regulatory functions and mechanisms remain unclear. Here, a novel circ0001470, originating from the porcine GRN gene, differentially expressed on day 18 versus day 32 of gestation in Meishan and Yorkshire pigs was screened. The circularization characteristic of circ0001470 was identified based on divergent primer amplification, Sanger sequencing, RNase digestion, and RNA nuclear-cytoplasmic fractionation. Functionally, circ0001470 can promote cell proliferation and cycle progression of endometrial epithelial cells (EECs) and also inhibit apoptosis of EECs using CCK-8 assays and flow cytometry analyses. Mechanistically, bioinformatics database prediction, luciferase screening, RNA immunoprecipitation (RIP), RNA-pull down, and FISH co-localization experiments r
Contradicts
CYP46A1 overexpression in aged mice shows diminished efficacy compared to young animals, suggesting a therapeutic window limitation
Contradicts
Cholesterol 24-hydroxylase: Brain cholesterol metabolism and beyond.
Abstract
Dysfunctions in brain cholesterol homeostasis have been extensively related to brain disorders. The major elimination pathway of brain cholesterol is its hydroxylation into 24 (S)-hydroxycholesterol by the cholesterol 24-hydroxylase (CYP46A1). Interestingly, there seems to be an association between CYP46A1 and high-order brain functions, in a sense that increased expression of this hydroxylase improves cognition, while a reduction leads to a poor cognitive performance. Moreover, increasing amount of epidemiological, biochemical and molecular evidence, suggests that CYP46A1 has a role in the pathogenesis or progression of neurodegenerative disorders, in which up-regulation of this enzyme is clearly beneficial. However, the mechanisms underlying these effects are poorly understood, which highlights the importance of studies that further explore the role of CYP46A1 in the central nervous system. In this review we summarize the major findings regarding CYP46A1, and highlight the several re
Contradicts
24S-hydroxycholesterol: Cellular effects and variations in brain diseases.
Abstract
The adult brain exhibits a characteristic cholesterol homeostasis, with low synthesis rate and active catabolism. Brain cholesterol turnover is possible thanks to the action of the enzyme cytochrome P450 46A1 (CYP46A1) or 24-cholesterol hydroxylase, that transforms cholesterol into 24S-hydroxycholesterol (24S-HC). But before crossing the blood-brain barrier (BBB), this oxysterol, that is the most abundant in the brain, can act locally, affecting the functioning of neurons, astrocytes, oligodendrocytes, and vascular cells. The first part of this review addresses different aspects of 24S-HC production and elimination from the brain. The second part concentrates in the effects of 24S-HC at the cellular level, describing how this oxysterol affects cell viability, amyloid β production, neurotransmission, and transcriptional activity. Finally, the role of 24S-HC in Alzheimer, Huntington and Parkinson diseases, multiple sclerosis and amyotrophic lateral sclerosis, as well as the possibility o
📖 Linked Papers (30)Export BibTeX ↗
The cholesterol 24-hydroxylase CYP46A1 promotes α-synuclein pathology in Parkinson's disease.
PLoS biology (2025) · PubMed:39964974 ↗
9 figures
Fig 1
CYP46A1 and 24-OHC are up-regulated in PD patients and PD model mice.
Fig 2
α-Syn pathology and its spread are significantly reduced after CYP46A1 removal in vivo.
Metabolic orchestration of cell death by AMPK-mediated phosphorylation of RIPK1.
Science (2023) · PubMed:37384704 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
ATAD3A oligomerization promotes neuropathology and cognitive deficits in Alzheimer's disease models.
Nature communications (2022) · PubMed:35236834 ↗
7 figures
Fig. 1
Aberrant ATAD3A oligomerization in AD models.
Fig. 2
ATAD3A oligomerization impairs MAM integrity under AD conditions.
TREM2, microglia, and Alzheimer's disease.
Mech Ageing Dev (2021) · PubMed:33516818 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
24S-hydroxycholesterol: Cellular effects and variations in brain diseases.
Journal of neurochemistry (2021) · PubMed:33118626 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Depression and post-traumatic stress during major social unrest in Hong Kong: a 10-year prospective cohort study.
Lancet (London, England) (2020) · PubMed:31928765 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Dysregulated Cholesterol Clearance via CYP46A1 Contributes to Cerebellar Sterol Imbalance in Mecp2-Null Mice.
International journal of molecular sciences (2026) · PubMed:41828569 ↗
No figures
Efavirenz treatment improves retinal vaso-obliteration and pathological neovascularization in a mouse model of retinopathy of prematurity.
Frontiers in medicine (2026) · PubMed:41810243 ↗
No figures
How cytochrome P450 enzymes in humans are involved in Parkinson's disease: a literature review.
Neuroscience (2026) · PubMed:41730497 ↗
No figures
Radiosynthesis and Evaluation of 18F‑Labeled Deuterated Radioligand for Positron Emission Tomography Imaging of Cholesterol 24-Hydroxylase.
ACS medicinal chemistry letters (2026) · PubMed:41704371 ↗
No figures
ABC Transporters, APOE, CYP46A1, and LRP1 Gene Polymorphisms as Markers of Dementia Development in Patients with Hyperlipidemia.
International journal of molecular sciences (2025) · PubMed:41226793 ↗
No figures
📙 Related Wiki Pages (15)
ANG — AngiogeningeneANG ProteinproteinCYP46A1 — Cholesterol 24-HydroxylasegeneAxon Guidance Pathways in NeurodegeneratmechanismComputational Drug Discovery in NeurodegmechanismAAV Capsid Engineering for CNS-Targeted ideaHippocampal Granule Cells in NeurodegenecellEpigenetic Dysregulation in NeurodegenermechanismmiRNA Regulatory Pathway in NeurodegenermechanismRibonuclease κ and Circular RNAs: A New mechanismTunneling Nanotubes in NeurodegenerationmechanismSigma-1 Receptor Agonists for NeurodegentherapeuticBDNF Signaling Pathway in NeurodegeneratmechanismGlobus Pallidus Externus GABAergic in NecellGSK3 Beta in Neurodegenerationmechanism
🏥 Translation
🧬 3D Protein Structure — CYP46A1
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for CYP46A1 from GTEx v10.
💉 Clinical Trials (7)Relevance: 79%
0
Active
Active
0
Completed
Completed
292
Total Enrolled
Total Enrolled
PHASE1
Highest Phase
Highest Phase
COMPLETED·NCT03706885 · Case Western Reserve University
5 enrolled · 2018-05-05 · → 2022-01-28
This will be a two-center, placebo controlled blinded clinical trial to evaluate the safety and tolerability of efavirenz (EFV) in 36 clinically stable subjects with mild cognitive impairment/early de
Alzheimer Disease, Early Onset
Sustiva Pill
ACTIVE_NOT_RECRUITING·NCT05541627 · Brainvectis, a subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio)
5 enrolled · 2022-10-12 · → 2024-04-04
A Phase I/II Dose-Finding Study to Evaluate Striatal Administration of AB-1001 (previously BV-101) in Adults with Early Manifest Huntington's Disease
Huntington Disease
AB-1001 Gene Therapy
RAPA-501 Therapy for ALSPHASE2
RECRUITING·NCT04220190 · Rapa Therapeutics LLC
41 enrolled · 2025-01-02 · → 2026-07-01
RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).
Amyotrophic Lateral Sclerosis
RAPA-501 Autologous T stem cells
COMPLETED·NCT03955380 · Prof. Dr. Dieter Willbold
24 enrolled · 2018-12-12 · → 2019-04-03
This is a single-center multiple-ascending-dose clinical trial assessing the safety and tolerability of oral dosing of Contraloid acetate in healthy volunteers. The study drug Contraloid (alias RD2, a
Alzheimer Dementia Alzheimer Disease
Contraloid
UNKNOWN·NCT04820881 · Washington D.C. Veterans Affairs Medical Center
60 enrolled · 2021-10-01 · → 2024-09
This grant award entitled, "Cerebrovascular Reactivity and Oxygen Metabolism as Markers for Neurodegeneration after Traumatic Brain Injury" (hereafter, "Neurovascular Study"), aims to determine if neu
Neurodegenerative Diseases
Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's DiseasePHASE1
NOT_YET_RECRUITING·NCT07212088 · iCamuno Biotherapeutics Ltd.
12 enrolled · 2026-02-28 · → 2027-12-15
Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments p
Parkinson Disease
ALC01 therapy
COMPLETED·NCT02405182 · University of Alberta
145 enrolled · 2014-09 · → 2019-03
Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Increasing age is an important risk f
Amyotrophic Lateral Sclerosis ALS Motor Neuron Diseases
Magnetic Resonance Imaging
🧬 Genetic Counter-Evidence — CYP46A1
12 Pathogenic / Likely-Pathogenic
35 Uncertain Significance
47 Total variants loaded
Associated conditions: See cases
Pathogenic / Likely-Pathogenic (10 shown)
| ClinVar ID | Variant | Significance | Conditions | Consequence | Review Status |
|---|---|---|---|---|---|
| 929832 | GRCh37/hg19 14q32.2-32.33(chr14:96829290-107287663)x1 | pathogenic | See cases | — | criteria provided, single submitter |
| 688581 | GRCh37/hg19 14q32.2-32.33(chr14:99794230-107285437)x3 | pathogenic | — | — | no assertion criteria provided |
| 687996 | GRCh37/hg19 14q32.12-32.33(chr14:91969028-107285437)x3 | pathogenic | — | — | no assertion criteria provided |
| 625815 | GRCh37/hg19 14q32.2-32.31(chr14:99737888-101847855) | likely pathogenic | — | — | criteria provided, single submitter |
| 4682850 | GRCh37/hg19 14q32.2-32.33(chr14:97521552-107285437)x3 | pathogenic | — | — | criteria provided, single submitter |
| 443977 | GRCh37/hg19 14q11.2-32.33(chr14:20511673-107285437) | pathogenic | See cases | — | no assertion criteria provided |
| 442718 | GRCh37/hg19 14q24.2-32.33(chr14:73750741-107285437)x3 | pathogenic | See cases | — | no assertion criteria provided |
| 2684743 | GRCh37/hg19 14q31.3-32.33(chr14:88580184-107285437)x3 | pathogenic | — | — | criteria provided, single submitter |
| 2684728 | GRCh37/hg19 14q23.1-32.33(chr14:58894502-107227240)x3 | pathogenic | — | — | criteria provided, single submitter |
| 1807775 | GRCh37/hg19 14q31.2-32.33(chr14:84537502-107285437)x3 | pathogenic | — | — | criteria provided, single submitter |
Uncertain Significance (35 variants) — expand
| ClinVar ID | Variant | Significance | Conditions | Consequence | Review Status |
|---|---|---|---|---|---|
| 564133 | GRCh37/hg19 14q32.2(chr14:98924025-101159952)x3 | uncertain significance | — | — | no assertion criteria provided |
| 4836739 | NM_006668.2(CYP46A1):c.1399C>A (p.Arg467Ser) | uncertain significance | — | — | criteria provided, single submitter |
| 4835657 | NM_006668.2(CYP46A1):c.1322A>G (p.Gln441Arg) | uncertain significance | — | — | criteria provided, single submitter |
| 4658149 | NM_006668.2(CYP46A1):c.1442C>A (p.Pro481His) | uncertain significance | — | — | criteria provided, single submitter |
| 4658148 | NM_006668.2(CYP46A1):c.772G>A (p.Val258Ile) | uncertain significance | — | — | criteria provided, single submitter |
| 4658147 | NM_006668.2(CYP46A1):c.1333A>G (p.Met445Val) | uncertain significance | — | — | criteria provided, single submitter |
| 4658146 | NM_006668.2(CYP46A1):c.1303C>T (p.Arg435Cys) | uncertain significance | — | — | criteria provided, single submitter |
| 4658145 | NM_006668.2(CYP46A1):c.1382G>A (p.Arg461Gln) | uncertain significance | — | — | criteria provided, single submitter |
| 4236993 | NM_006668.2(CYP46A1):c.256A>G (p.Ile86Val) | uncertain significance | — | — | criteria provided, single submitter |
| 4236991 | NM_006668.2(CYP46A1):c.616G>A (p.Gly206Ser) | uncertain significance | — | — | criteria provided, single submitter |
| 4236990 | NM_006668.2(CYP46A1):c.818C>T (p.Ala273Val) | uncertain significance | — | — | criteria provided, single submitter |
| 4236989 | NM_006668.2(CYP46A1):c.867C>G (p.Asp289Glu) | uncertain significance | — | — | criteria provided, single submitter |
| 4236988 | NM_006668.2(CYP46A1):c.1492C>A (p.Pro498Thr) | uncertain significance | — | — | criteria provided, single submitter |
| 4236986 | NM_006668.2(CYP46A1):c.48C>A (p.Phe16Leu) | uncertain significance | — | — | criteria provided, single submitter |
| 4008940 | NM_006668.2(CYP46A1):c.1033G>A (p.Glu345Lys) | uncertain significance | — | — | criteria provided, single submitter |
| 4008939 | NM_006668.2(CYP46A1):c.610C>G (p.Leu204Val) | uncertain significance | — | — | criteria provided, single submitter |
| 4008938 | NM_006668.2(CYP46A1):c.1465C>T (p.Arg489Cys) | uncertain significance | — | — | criteria provided, single submitter |
| 3837938 | NM_006668.2(CYP46A1):c.466A>G (p.Thr156Ala) | uncertain significance | — | — | criteria provided, single submitter |
| 3837937 | NM_006668.2(CYP46A1):c.1463C>T (p.Pro488Leu) | uncertain significance | — | — | criteria provided, single submitter |
| 3499286 | NM_006668.2(CYP46A1):c.396G>C (p.Glu132Asp) | uncertain significance | — | — | criteria provided, single submitter |
| 3499285 | NM_006668.2(CYP46A1):c.778C>T (p.Arg260Cys) | uncertain significance | — | — | criteria provided, single submitter |
| 3499284 | NM_006668.2(CYP46A1):c.722G>A (p.Arg241Gln) | uncertain significance | — | — | criteria provided, single submitter |
| 3499283 | NM_006668.2(CYP46A1):c.785G>A (p.Arg262Gln) | uncertain significance | — | — | criteria provided, single submitter |
| 3499282 | NM_006668.2(CYP46A1):c.40C>G (p.Leu14Val) | uncertain significance | — | — | criteria provided, single submitter |
| 3244102 | NC_000014.8:g.(?_99375322)_(101142891_?)dup | uncertain significance | — | — | criteria provided, single submitter |
| 3079643 | NM_006668.2(CYP46A1):c.959G>A (p.Arg320His) | uncertain significance | — | — | criteria provided, single submitter |
| 3079642 | NM_006668.2(CYP46A1):c.811G>A (p.Val271Ile) | uncertain significance | — | — | criteria provided, single submitter |
| 3079640 | NM_006668.2(CYP46A1):c.1487C>T (p.Pro496Leu) | uncertain significance | — | — | criteria provided, single submitter |
| 3079639 | NM_006668.2(CYP46A1):c.1468G>A (p.Gly490Ser) | uncertain significance | — | — | criteria provided, single submitter |
| 3079638 | NM_006668.2(CYP46A1):c.1399C>T (p.Arg467Cys) | uncertain significance | — | — | criteria provided, single submitter |
... and 5 more. View on NCBI →
No DepMap CRISPR Chronos data found for CYP46A1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
6.0 years
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↘
Falling
7d Momentum
▼ 2.4%
Volatility
Medium
0.0473
Events (7d)
4
Price History
▼25.5%💾 Resource Usage
LLM Tokens
32,728
$0.1964
Total Cost
$0.1964
🧭 Related
🕸 Knowledge Subgraph (200 edges)Showing top 50 of 200 edges by weightCentered on CYP46A1
Top relations:causes (26)regulates (23)associated with (23)activates (22)modulates (17)co discussed (15)
🔍 Show all 50 edges across 15 relations
activates (14)
ASM→CeramideHMGCR→cholesterol_synthesisSPHK1→sphingosine_kinase_activityEVP-6124→alpha7_nAChR24-hydroxycholesterol→LXR nuclear receptors
▸ Show 9 more
associated with (2)
biomarker for (1)
catalyzes (1)
causes (13)
SMPD1 mutations→Niemann-Pick disease type AAPP_processing→amyloid_beta_productionCYP46A1→24-hydroxycholesterolCYP46A1→24S-hydroxycholesterolsemagacestat→Notch_signaling
▸ Show 8 more
Semagacestat→Alzheimer_diseaseSMPD1 mutations→NeurodegenerationLysosomal membrane permeabilization→Cathepsin releaseAcid sphingomyelinase→Lysosomal destabilizationCeramide accumulation→Lysosomal membrane permeabilizationcholesterol→neuronal accumulation24-hydroxycholesterol→oxidative stress24-hydroxycholesterol→neuroinflammation
co localizes in (1)
disrupts (1)
inhibits (2)
modulates (2)
promotes (1)
protective against (2)
regulates (7)
risk factor for (1)
therapeutic target for (1)
🗺️ KG Entities (180)
24-hydroxycholesterol24S-hydroxycholesterol24S-hydroxycholesterol (low concentratAAV gene therapyAAV-mediated CYP46A1 deliveryAAV-mediated gene therapyABCA1ABCA1 modulatorsABCA1/LDLR/SREBF2AD-risk variantsADAM10AKTAPOEAPOE expressionAPPAPP_processingASMASM activityAcid sphingomyelinaseAcid sphingomyelinase / ceramide signaAlzheimer's diseaseAlzheimer_diseaseAmitriptylineApoptosisBACE1BACE1_clusteringBAXBeta-secretase / amyloidogenic pathwayCAV1CERS2CHATCHRNA7CNS cholesterol depletionCNS-selective ABCA1 modulatorsCYP46A1CYP46A1 deliveryCYP46A1 expressionCYP46A1 overexpressionCathepsin releaseCeramideCeramide accumulationCeramide levelsCholesterol 24-hydroxylase / brain choCholesterol efflux / lipid transportEVP-6124EVP_6124FLOT1HMGCRHuntington's diseaseJNKLDLRLRX activationLXR activationLXR nuclear receptorsLXR signalingLipid raft membrane organizationLysosomal destabilizationLysosomal membrane permeabilizationNLRP3NeurodegenerationNeuroprotectionNiemann-Pick disease type ANotch_signalingPSEN1Parkinson's diseaseSGMS1SGMS1/SGMS2SGMS2SMPD1SMPD1 mutationsSOAT1SPHK1SREBF2SREBF2 dysregulationSREBP processingSREBP signalingST3GAL2ST3GAL2/ST8SIA1ST8SIA1Selective ASM inhibitorsSemagacestatSphingolipid / ceramide signalingTAUUNC1062acetylcholine_synthesisalpha7_nAChRalpha7_nAChR_signalingalpha_secretase_activityamyloid clearanceamyloid loadamyloid pathologyamyloid-beta accumulationamyloid-beta pathologyamyloid-beta reductionamyloid_betaamyloid_beta_productionamyloidogenic_APP_processingbeta_secretase___amyloidogenic_pathwaybrain cholesterol eliminationceramide_biosynthesisceramide_metabolismceramide_productioncholesterolcholesterol effluxcholesterol homeostasis impairmentcholesterol reductioncholesterol_24_hydroxylase___brain_chocholesterol_biosynthesischolesterol_effluxcholesterol_efflux___lipid_transportcholesterol_esterificationcholesterol_homeostasischolesterol_metabolismcholesterol_sphingolipid_ratiocholesterol_synthesischolinergic_signalingcognitive outcomescompensatory upregulationde novo cholesterol synthesiselevated 24S-hydroxycholesterol+ 60 more
🔗 Dependency Graph (0 upstream, 3 downstream)
🧪 Adjacent Hypotheses10 siblings from the same analysis
Senescent Cell ASM-Complement Cascade Intervention
0.85SMPD1 · neurodegeneration · validated
Neutral Sphingomyelinase-2 Inhibition for Synaptic Protection in Neurodegeneration
0.84SMPD3 · neurodegeneration · validated
CYP46A1 Small Molecule Activator Therapy
0.82CYP46A1 · neurodegeneration · validated
CYP46A1-Mediated Cholesterol Reduction Prevents eIF2α-Driven Translation Stalling in Neuro
0.82CYP46A1 · neurodegeneration · validated
Selective Acid Sphingomyelinase Modulation Therapy
0.78SMPD1 · neurodegeneration · promoted
Selective Neutral Sphingomyelinase-2 Inhibition Therapy
0.73SMPD3 · neurodegeneration · promoted
Membrane Cholesterol Gradient Modulators
0.71ABCA1/LDLR/SREBF2 · neurodegeneration · promoted
Palmitoylation-Targeted BACE1 Trafficking Disruptors
0.69BACE1 · neurodegeneration · proposed
Sphingomyelin Synthase Activators for Raft Remodeling
0.69SGMS1/SGMS2 · neurodegeneration · promoted
Ganglioside Rebalancing Therapy
0.69ST3GAL2/ST8SIA1 · neurodegeneration · proposed
🗣 Debate PerspectivesHypothesis Debate | 6 rounds | 2026-04-27
🔮 Predictions
🔎 Predictions vs Observations5 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| If hypothesis is true, intervention focus on dose-finding and safety in early-stage AD patients, with 24-OHC levels in cerebrospinal fluid (CSF) serving as a reliable pharmacodynamic biomarker | focus on dose-finding and safety in early-stage AD patients, with 24-OHC levels in cerebrospinal fluid (CSF) serving as a reliable pharmacodynamic biomarker | — no observation — | pending | 0.85 |
| If hypothesis is true, intervention employ adaptive designs with CSF biomarker endpoints (Aβ42/40 ratio, phospho-tau 181/217) alongside cognitive assessments | employ adaptive designs with CSF biomarker endpoints (Aβ42/40 ratio, phospho-tau 181/217) alongside cognitive assessments | — no observation — | pending | 0.85 |
| If hypothesis is true, intervention deplete cholesterol below physiological levels, impairing synaptic function | deplete cholesterol below physiological levels, impairing synaptic function | — no observation — | pending | 0.85 |
| If hypothesis is true, intervention accelerate development and reduce costs | accelerate development and reduce costs | — no observation — | pending | 0.85 |
| If hypothesis is true, intervention be durable without repeat dosing | be durable without repeat dosing | — no observation — | pending | 0.85 |
🔮 Falsifiable Predictions (5)
pendingconf 85%
If hypothesis is true, intervention focus on dose-finding and safety in early-stage AD patients, with 24-OHC levels in cerebrospinal fluid (CSF) serving as a reliable pharmacodynamic biomarker
Predicted outcome: focus on dose-finding and safety in early-stage AD patients, with 24-OHC levels in cerebrospinal fluid (CSF) serving as a reliable pharmacodynamic bio
Falsification: Intervention fails to focus on dose-finding and safety in early-stage AD patients, with 24-OHC levels in cerebrospinal fluid (CSF) serving as a reliable pharmacodynamic biomarker
pendingconf 85%
If hypothesis is true, intervention employ adaptive designs with CSF biomarker endpoints (Aβ42/40 ratio, phospho-tau 181/217) alongside cognitive assessments
Predicted outcome: employ adaptive designs with CSF biomarker endpoints (Aβ42/40 ratio, phospho-tau 181/217) alongside cognitive assessments
Falsification: Intervention fails to employ adaptive designs with CSF biomarker endpoints (Aβ42/40 ratio, phospho-tau 181/217) alongside cognitive assessments
pendingconf 85%
If hypothesis is true, intervention deplete cholesterol below physiological levels, impairing synaptic function
Predicted outcome: deplete cholesterol below physiological levels, impairing synaptic function
Falsification: Intervention fails to deplete cholesterol below physiological levels, impairing synaptic function
pendingconf 85%
If hypothesis is true, intervention accelerate development and reduce costs
Predicted outcome: accelerate development and reduce costs
Falsification: Intervention fails to accelerate development and reduce costs
pendingconf 85%
If hypothesis is true, intervention be durable without repeat dosing
Predicted outcome: be durable without repeat dosing
Falsification: Intervention fails to be durable without repeat dosing
📖 References (14)
- Cholesterol 24-Hydroxylation by CYP46A1: Benefits of Modulation for Brain Diseases.Petrov AM et al.. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics (2019)
- PMID:19654569
- The normalizing effects of the CYP46A1 activator efavirenz on retinal sterol levels and risk factors for glaucoma in Apoj["El-Darzi Nicole" et al.. Cellular and molecular life sciences : CMLS (2023)
- PMID:15975088
- An unusual cause of pulmonary embolism.M Bruyneel; A Peeters; P G Silance; S Alard; D Horn. Thorax (2015)
- Complement and microglia mediate early synapse loss in Alzheimer mouse models.Hong S et al.. Science (2016)
- Gamma Entrainment Binds Higher-Order Brain Regions and Offers Neuroprotection.["Adaikkan C" et al.. Neuron (2019)
- TREM2, microglia, and Alzheimer's disease.Qin Q et al.. Mech Ageing Dev (2021)
- ATAD3A oligomerization promotes neuropathology and cognitive deficits in Alzheimer's disease models.Zhao Y et al.. Nature communications (2022)
- Metabolic orchestration of cell death by AMPK-mediated phosphorylation of RIPK1.Zhang T et al.. Science (2023)
- Brain cholesterol and Alzheimer's disease: challenges and opportunities in probe and drug development.Ahmed H et al.. Brain : a journal of neurology (2024)
- Vitamin C deficiency aggravates tumor necrosis factor α-induced insulin resistance.["Qing Z" et al.. European journal of pharmacology (2018)
- Depression and post-traumatic stress during major social unrest in Hong Kong: a 10-year prospective cohort study.["Ni M" et al.. Lancet (London, England) (2020)
- ReplyCrippa Stefano; Falconi Massimo. Clinical Gastroenterology and Hepatology (2022)
Related Entities
▸Metadata
| status | proposed |
| _schema_version | 1 |
| hypothesis_type | None |
📊 Evidence Profile
Foundational
Evidence Balance
+0%
Certainty
100%
Debates
0
Incoming
5874
Outgoing
4258
0 supporting
0 contradicting
0 neutral
🌍 Provenance Graph
8 nodes, 16 edges
derives from (14)
hypothesis-h-2600483e→analysis-SDA-2026-04-01-gap-lianalysis-SDA-2026-04-01-gap-li→hypothesis-h-de0d4364hypothesis-h-de0d4364→analysis-SDA-2026-04-01-gap-lianalysis-SDA-2026-04-01-gap-li→hypothesis-h-9d29bfe5hypothesis-h-9d29bfe5→analysis-SDA-2026-04-01-gap-li
▸ Show 9 more
analysis-SDA-2026-04-01-gap-li→hypothesis-h-2600483eanalysis-SDA-2026-04-01-gap-li→hypothesis-h-12599989hypothesis-h-12599989→analysis-SDA-2026-04-01-gap-lianalysis-SDA-2026-04-01-gap-li→hypothesis-h-fdb07848hypothesis-h-fdb07848→analysis-SDA-2026-04-01-gap-lianalysis-SDA-2026-04-01-gap-li→hypothesis-h-a015e80ehypothesis-h-a015e80e→analysis-SDA-2026-04-01-gap-lianalysis-SDA-2026-04-01-gap-li→hypothesis-h-441b25bahypothesis-h-441b25ba→analysis-SDA-2026-04-01-gap-li
🗣 Debate History2 sessions
This artifact has no version history yet.
Linked Artifacts (10126)
🧬 Related Hypotheses — same target / disease (8)
CYP46A1 Small Molecule Activator Therapy
Score: 0.819 · Target: CYP46A1 · neurodegeneration
CYP46A1-Mediated Cholesterol Reduction Prevents eIF2α-Driven Translation Stalling in Neuro
Score: 0.819 · Target: CYP46A1 · neurodegeneration
TREM2-Mediated Cholesterol Dysregulation in Microglial Senescence
Score: 0.666 · Target: CYP46A1 · neurodegeneration
CYP46A1 Suppression for Tau-Mediated Neurodegeneration
Score: 0.642 · Target: CYP46A1 · neurodegeneration
CYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microglial Senescence Reversal
Score: 0.555 · Target: CYP46A1 · neurodegeneration
CYP46A1 Activation as a Therapeutic Strategy to Restore Neuronal Cholesterol Efflux and Re
Score: 0.550 · Target: CYP46A1 · lipidomics
Focused Ultrasound-Enhanced CYP46A1 Gene Therapy for Neurodegeneration
Score: 0.380 · Target: CYP46A1 · neurodegeneration
CYP46A1 Inhibition Therapy for Neurodegeneration
Score: 0.380 · Target: CYP46A1 · neurodegeneration
Reference URLs
Embed this artifact
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
HTML iframe
<iframe src="http://scidex.ai/artifact/hypothesis-h-2600483e?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
Markdown link
[CYP46A1 Overexpression Gene Therapy](http://scidex.ai/artifact/hypothesis-h-2600483e)
Direct URL
http://scidex.ai/artifact/hypothesis-h-2600483e
Preview
🔄 Adjacent Artifacts
Recommended based on your interests
💬 Discussion
Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.